title: Rituximab treatment strategy for patients with diffuse large B-cell lymphoma after first-line therapy: a systematic review and meta-analysis.
abstract: BACKGROUND
  Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly prolonged event-free survival in first-line chemotherapy for patients with diffuse large B-cell lymphoma (DLBCL). But relapse and refractory DLBCL occur frequently. Although rituximab is effective, its role in salvage therapy after autologous transplant remains unclear. Maintenance therapy with rituximab in responding patients after first line chemotherapy may be a useful novel approach capable of eradicating minimal residual disease and to bring survival benefit. This systematic review and meta-analysis evaluated the effects of rituximab maintenance treatment and salvage therapy of patients with DLBCL.
  
  
  METHODS
  We performed a systematic review and meta-analysis of randomized controlled trials and compared rituximab maintenance or salvage therapy at relapse with observation. We searched the Cochrane Library, PubMed, EMBASE, conference proceedings, databases of ongoing trials, and references of published trials. Two reviewers independently assessed the quality of the trials and extracted data. Hazard ratios for time-to-event data were estimated and pooled.
  
  
  RESULTS
  Seven trials including 1470 DLBCL patients were included in this systematic review and meta-analysis. Patients treated with maintenance rituximab have better overall survival (OS) and event-free survival (EFS) than patients in the observation arm, but there was no statistical significance. Patients who received rituximab salvage therapy for relapse or refractory DLBCL have statistically significantly better OS [HR of death = 0.72, 95% CI (0.55-0.94), P = 0.02], progression-free survival (PFS) [HR = 0.61, 95% CI (0.52-0.72), P < 0.05], odds ratio (OR) [RR = 1.26, 95% CI (1.07-1.47), P = 0.004] than patients in the observation arm. The rate of infection-related adverse events was higher with rituximab treatment [RR = 1.37, 95% CI = (1.14 - 1.65) P =0.001].
  
  
  CONCLUSIONS
  After first-line chemotherapy, the two rituximab-combined treatment strategies, including maintenance and salvage therapies can bring survival benefit. But due to the few studies, the low methodological quality assessment and the low outcome evidence quality, it's not confirmed that the two strategies are better than normal chemotherapy regimens. More high-quality randomized controlled trials are still needed to provide reliable evidence. The higher rate of infections after rituximab therapy should be taken into consideration when making treatment decisions.
authors: Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Chengdu, Sichuan 610000, China.
authors: Yuan-Rong
authors: YR
authors: Ren
authors: Yong-Dong
authors: YD
authors: Jin
authors: Zhi-Hui
authors: ZH
authors: Zhang
authors: Li
authors: L
authors: Li
authors: Ping
authors: P
authors: Wu
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab
references: N Engl J Med. 2002 Jan 24;346(4):235-42
references: 11807147
references: Semin Oncol. 2002 Apr;29(2 Suppl 6):18-22
references: 12040530
references: Control Clin Trials. 1996 Feb;17(1):1-12
references: 8721797
references: Stat Med. 1998 Dec 30;17(24):2815-34
references: 9921604
references: Lancet Oncol. 2006 May;7(5):379-91
references: 16648042
references: J Clin Oncol. 2006 Jul 1;24(19):3121-7
references: 16754935
references: Leuk Lymphoma. 2006 Jun;47(6):1013-7
references: 16840190
references: Blood. 2006 Nov 15;108(10):3295-301
references: 16873669
references: Ann Hematol. 2007 Feb;86(2):107-15
references: 17103169
references: Leuk Lymphoma. 2006 Dec;47(12):2558-66
references: 17169800
references: Blood. 2008 Jan 15;111(2):537-43
references: 17971487
references: Leuk Lymphoma. 2008 Jan;49(1):152-3
references: 18203024
references: J Natl Cancer Inst. 2009 Feb 18;101(4):248-55
references: 19211444
references: Ann Oncol. 2009 Dec;20(12):1985-92
references: 19567453
references: Clin Lymphoma Myeloma Leuk. 2010 Apr;10(2):125-8
references: 20371445
references: J Clin Oncol. 2010 Sep 20;28(27):4184-90
references: 20660832
references: J Clin Exp Hematop. 2011;51(1):1-5
references: 21628854
references: Chest. 2011 Jul;140(1):117-26
references: 21436247
references: Lancet Oncol. 2011 Oct;12(11):984-5
references: 21940215
references: J Natl Cancer Inst. 2011 Dec 7;103(23):1799-806
references: 22021664
references: Curr Opin Oncol. 2012 Sep;24(5):461-5
references: 22759738
references: Ann Hematol. 2013 Nov;92(11):1451-9
references: 23748882